Category: Zacks Small Cap Research

1676869707197690 / 968 POSTS
By Brian Marckx, CFANYSE:VNRXREAD THE FULL VNRX RESEARCH REPORTQ3 Results / Operational and Business Update:VoltionRx (NYSE:VNRX) reported Q3 results and provided a business update. Relative to the financials, operating expenses of $4.5M were about 7 ...
By Lisa ThompsonNASDAQ:CSSEREAD THE FULL CSSE RESEARCH REPORTChicken Soup for the Soul Entertainment (NASDAQ:CSSE) reported Q3 numbers that showed remarkable progress over last year both for the quarter and the nine months. It has built a strong busi ...
By Steven Ralston, CFAOTC:MEECREAD THE FULL MEEC RESEARCH REPORTSummaryManagement has initiated a patent strategy in order to monetize aspects of SEA Technology that have been employed at over 100 EGUs. An IP (Intellectual Property) law firm has been ...
By John Vandermosten, CFANASDAQ:TTNPREAD THE FULL TTNP RESEARCH REPORTThird Quarter 2018 Financial and Operational ResultsTitan Pharmaceuticals, Inc. (NASDAQ:TTNP) reported third quarter 2018 results on November 14th in a press release and in a subse ...
By David Bautz, PhDNASDAQ:BVXVREAD THE FULL BVXV RESEARCH REPORTBusiness UpdateEnrollment of the First Influenza Season Cohort in Phase 3 Trial of M-001 CompleteBiondVax Pharmaceuticals,Ltd. (NASDAQ:BVXV) is a biopharmaceutical company developing a u ...
By Brian Marckx, CFANASDAQ:CYRXREAD THE FULL CYRX RESEARCH REPORTQ3 2018: Another Very Strong Quarter With New Records in Several Categories. Operating Leverage Continues To Solidify… Another very strong quarter for CryoPort (NASDAQ:CYRX) with Q3 set ...
By Steven Ralston, CFATSX:WML.VREAD THE FULL WML.V RESEARCH REPORTCEO Wealth Minerals Hosts Conference CallOn November 7, 2018, Henk Van Alphen, CEO of Wealth Minerals (TSX:WML.V), conducted a conference call to update the investment community on the ...
By David Bautz, PhDNYSE:OGENREAD THE FULL OGEN RESEARCH REPORTBusiness UpdateAdditional Clinical Trial Sites Open in Europe for Phase 2 Trial of AG013Oragenics, Inc. (NYSE:OGEN) is currently conducting a Phase 2, double blind, placebo controlled clin ...
By David Bautz, PhDNASDAQ:SNGXREAD THE FULL SNGX RESEARCH REPORTFinancial UpdateOn Nov. 9, 2018, Soligenix (NASDAQ:SNGX) announced financial results for the third quarter of 2018. The company reported revenues of $1.4 million in the third quarter of ...
By David Bautz, PhDNASDAQ:TNXPREAD THE FULL TNXP RESEARCH REPORTBusiness UpdateNew Phase 3 Trial for TNX-102 SL to Initiate in 1Q19On October 31, 2018, Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) announced that the company will be initiating a ...
1676869707197690 / 968 POSTS